Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.
Pharmacogenomics
; 23(1): 15-34, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-34905955
ABSTRACT
Aim:
Polymorphisms at LPA, LDLR, APOE, APOC1, MYLIP and ABCG2 are attractive targets for assessment of their impact on lipid-lowering therapy with rosuvastatin. The present study investigated whether polymorphisms at these genes are associated with the risk of coronary artery disease (CAD) development, and reduction of atherogenic lipids and carotid intima-media thickness (CIMT) in CAD patients, taking rosuvastatin. Materials &methods:
190 CAD patients and 1697 subjects were enrolled in pharmacogenetic and genetic association study, respectively. SNP genotyping was done using the MassARRAY-4 system.Results:
MYLIP rs6924995, rs3757354, APOC1 rs445925, LDLR rs6511720, APOE rs7412, ABCG2 rs2199936, rs1481012 variants were significantly associated with CAD susceptibility (p = 0.016, 0.0003, <0.0001, <0.0001, 0.013, 0.016, 0.0035, respectively), as well as with CIMT regression (except ABCG2 variants; p = 0.05, 0.039, 0.039, 0.016, 0.0065), and changes in plasma lipids during rosuvastatin therapy.Conclusion:
The studied polymorphisms possess pleiotropic effects on plasma lipids and CIMT, CAD susceptibility, and determine lipid-lowering response to rosuvastatin.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Doença da Artéria Coronariana
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Espessura Intima-Media Carotídea
/
Rosuvastatina Cálcica
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article